Yili Wang

Publications (13)22.26 Total impact

• Article: Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors.

  Yili Wang, Steven V O'Neil, John A Wos, Kofi A Oppong, Michael C Laufersweiler, David L Soper, Christopher D Ellis, Mark W Baize, Amy N Fancher, Wei Lu, Maureen K Suchanek, Richard L Wang, William P Schwecke, Charles A Cruze, Maria Buchalova, Marina Belkin, Biswanath De, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: Peptidomimetic compounds possessing a caprolactam ring constraint were prepared and evaluated as interleukin-1beta converting enzyme (ICE) inhibitors. The caprolactam ring was used to constrain the P3 region of our inhibitors. This strategy proved to be effective for the synthesis of ICE inhibitors, maintaining key hydrogen bond interactions with the enzyme and invoking a preferred conformation for binding. Several compounds exhibited IC(50) values less than 10nM in a caspase-1 enzyme assay and less than 100nM in a THP-1 whole cell assay measuring IL-1beta production. Two compounds, 13c and 13j, were found to have good oral bioavailability (>50%) in rats when administered as prodrugs.
  Bioorganic & Medicinal Chemistry 03/2007; 15(3):1311-22. · 2.92 Impact Factor
• Article: Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme (ICE) inhibitors.

  David L Soper, Justin X Sheville, Steven V O'Neil, Yili Wang, Michael C Laufersweiler, Kofi A Oppong, John A Wos, Christopher D Ellis, Mark W Baize, Jack J Chen, [......], Richard L Wang, William P Schwecke, Charles A Cruze, Maria Buchalova, Marina Belkin, Fred Wireko, Amanda Ritter, Biswanath De, Difei Wang, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: An 8,5-fused bicyclic peptidomimetic ring system generated by a stereoselective ring metathesis reaction was elaborated into potent inhibitors of interleukin-1beta converting enzyme (ICE, caspase-1). Multiple compounds were found that exhibited ICE IC50 values < 10 nM and were selective over caspase-3 and caspase-8. These active analogs generally possessed good activity (IC50 values < 100 nM) in a whole cell assay measuring IL-1beta production. Pharmacokinetic analysis of the ethyl acetal prodrug form of a selected active lead revealed a compound with a reasonable plasma half-life (1.1 h) and good oral bioavailability (30%).
  Bioorganic & Medicinal Chemistry 01/2007; 14(23):7880-92. · 2.92 Impact Factor
• Source

  Available from: xtals.org

  Article: Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis.

  Corey R Hopkins, Steven V O'neil, Michael C Laufersweiler, Yili Wang, Matthew Pokross, Marlene Mekel, Artem Evdokimov, Richard Walter, Maria Kontoyianni, Maria E Petrey, Georgios Sabatakos, Jeff T Roesgen, Eloise Richardson, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: The synthesis and structure-activity relationships of a novel series of N-sulfonyl-2-indole carboxamides that bind to peroxisome proliferator-activated receptor gamma (PPAR-gamma) are reported. Chemical optimization of the series led to the identification of 4q (IC(50)=50 nM) as a potent binding agent of PPAR-gamma. Also reported is preliminary cell based data suggesting the use of these compounds in the treatment of osteoporosis.
  Bioorganic & Medicinal Chemistry Letters 12/2006; 16(21):5659-63. · 2.55 Impact Factor
• Article: Synthesis and evaluation of thiazepines as interleukin-1beta converting enzyme (ICE) inhibitors.

  Christopher D Ellis, Kofi A Oppong, Michael C Laufersweiler, Steven V O'Neil, David L Soper, Yili Wang, John A Wos, Amy N Fancher, Wei Lu, Maureen K Suchanek, Richard L Wang, Biswanath De, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: A series of monocyclic thiazepine inhibitors of interleukin-1beta converting enzyme (ICE) were synthesized in eight steps from commercially available intermediates. In vitro biological evaluation showed the thiazepines to be moderately potent ICE inhibitors, with the most active compound exhibiting an IC50 value of 30 nM in an enzyme inhibition assay. Compounds of this class possessed good selectivity against the related enzymes caspase-3 and caspase-8.
  Bioorganic & Medicinal Chemistry Letters 10/2006; 16(18):4728-32. · 2.55 Impact Factor
• Article: Synthesis and evaluation of novel 1-(2-acylhydrazinocarbonyl)-cycloalkyl carboxamides as interleukin-1beta converting enzyme (ICE) inhibitors.

  David L Soper, Justin Sheville, Steven V O'Neil, Yili Wang, Michael C Laufersweiler, Kofi A Oppong, John A Wos, Christopher D Ellis, Amy N Fancher, Wei Lu, Maureen K Suchanek, Richard L Wang, Biswanath De, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: Novel 1-(2-acylhydrazinocarbonyl)cycloalkyl carboxamides were designed as peptidomimetic inhibitors of interleukin-1beta converting enzyme (ICE). A short synthesis was developed and moderately potent ICE inhibitors were identified (IC(50) values <100 nM). Most of the synthesized examples were selective for ICE versus the related cysteine proteases caspase-3 and caspase-8, although several dual-acting inhibitors of ICE and caspase-8 were identified. Several of the more potent ICE inhibitors were also shown to inhibit IL-1beta production in a whole cell assay (IC(50) < 500 nM).
  Bioorganic & Medicinal Chemistry Letters 08/2006; 16(16):4233-6. · 2.55 Impact Factor
• Article: Synthesis and evaluation of novel 8,6-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme inhibitors.

  Steven V O'Neil, Yili Wang, Michael C Laufersweiler, Kofi A Oppong, David L Soper, John A Wos, Christopher D Ellis, Mark W Baize, Gregory K Bosch, Amy N Fancher, Wei Lu, Maureen K Suchanek, Richard L Wang, Biswanath De, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: Two novel 8,6-fused bicyclic peptidomimetic ring systems were synthesized utilizing olefin metathesis as the key reaction for the formation of the eight-membered ring. Both peptidomimetic scaffolds were further elaborated into potent ICE inhibitors, with numerous compounds exhibiting caspase-1 IC(50)s less than 10nM.
  Bioorganic & Medicinal Chemistry Letters 01/2006; 15(24):5434-8. · 2.55 Impact Factor
• Article: Discovery of novel conformationally restricted diazocan peptidomimetics as inhibitors of interleukin-1beta synthesis.

  Kofi A Oppong, Christopher D Ellis, Michael C Laufersweiler, Steven V O'Neil, Yili Wang, David L Soper, Mark W Baize, John A Wos, Biswanath De, Gregory K Bosch, Amy N Fancher, Wei Lu, Maureen K Suchanek, Richard L Wang, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: A novel diazocan containing dipeptide mimetic was synthesized via reductive N-N bond cleavage of a pyrazolidino-pyrazolidine using Raney-Ni and evaluated as an ICE inhibitor. This versatile 8-membered ring containing scaffold possesses an N-5 ring nitrogen that was used to explore structure-activity relationships in a cell-based assay measuring inhibition of interleukin-1beta.
  Bioorganic & Medicinal Chemistry Letters 11/2005; 15(19):4291-4. · 2.55 Impact Factor
• Article: Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1beta-converting enzyme.

  Michael C Laufersweiler, Yili Wang, David L Soper, Maureen K Suchanek, Amy N Fancher, Wei Lu, Richard L Wang, Kofi A Oppong, Christopher D Ellis, Mark W Baize, Steven V O'Neil, John A Wos, Thomas P Demuth
  [show abstract] [hide abstract]
  ABSTRACT: The application of a tricyclic pyrrolopyrimidinone scaffold for the synthesis of peptidomimetic inhibitors of interleukin-1beta-converting enzyme (ICE) is reported. The synthesis of the tricyclic scaffold and conversion of it to a variety of target ICE inhibitors were accomplished in 4-5 steps. In vitro biological evaluation of the tricyclic pyrrolopyrimidinones revealed fair to good ICE inhibitors, with the most active compound exhibiting an IC50 of 14 nM in a caspase-1 enzyme binding assay.
  Bioorganic & Medicinal Chemistry Letters 11/2005; 15(19):4322-6. · 2.55 Impact Factor
• Article: The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis.

  David Lindsey Soper, Yili Wang, Biswanath De, Mitchell Anthony deLong, Michelle Jeanine Dirr, Michele Elaine Soehner, Mark Walden Lundy, Glen Edward Mieling, John August Wos
  [show abstract] [hide abstract]
  ABSTRACT: A series of prostaglandins selective for the human FP receptor have been synthesized and evaluated as potential therapeutics for the treatment of osteoporosis. The compounds proved to be potent (nanomolar binding affinity) and selective (> 100x) ligands for the human FP receptor in vitro, and increased bone volume in the ovariectomized rat in vivo.
  Advances in experimental medicine and biology 02/2002; 507:303-7. · 1.09 Impact Factor
• Article: Synthesis and Biological Evaluation of Prostaglandin-F Alkylphosphinic Acid Derivatives as Bone Anabolic Agents for the Treatment of Osteoporosis

  David L. Soper, Jared B. J. Milbank, Glen E. Mieling, Michelle J. Dirr, Andrew S. Kende, Robin Cooper, Webster S. S. Jee, Wei Yao, Jian Liang Chen, Mark Bodman, Mark W. Lundy, Biswanath De, Mark E. Stella, Frank H. Ebetino, Yili Wang, Mitchell A. deLong, John A. Wos
  [show abstract] [hide abstract]
  ABSTRACT: A series of novel C1 alkylphosphinic acid analogues of the prostaglandin-F family have been evaluated at the eight human prostaglandin receptors for potential use in the treatment of osteoporosis. Using molecular modeling as a tool for structure-based drug design, we have discovered that the phosphinic acid moiety (P(O)(OH)R) behaves as an isostere for the C1 carboxylic acid in the human prostaglandin FP binding assay in vitro and possesses enhanced hFP receptor selectivity when compared to the parent carboxylic acid. When evaluated in vivo, the methyl phosphinic acid analogue (4b) produced a bone anabolic response in rats, returning bone mineral density (BMD) to intact levels in the distal femur in the ovariectomized rat (OVX) model. These results suggest that prostaglandins of this class may be useful agents in the treatment of diseases associated with bone loss.
  10/2001;
• Article: An Efficient Synthesis of 3-Hetero-13,14-dihydro Prostaglandin F1α Analogues

  Jianxin Gu, Michelle J. Dirr, Yili Wang, David L. Soper, Biswanath De, John A. Wos, Carl R. Johnson
  [show abstract] [hide abstract]
  ABSTRACT: A new class of 3-hetero-13,14-dihydro prostaglandin F1α analogues was synthesized from a common intermediate. The latter was constructed via a two-step, three-component process. The lower chain, containing the 15-(phenoxymethyl) group, was synthesized in enantiopure form using Jacobsen's (salen)Co-catalyzed kinetic resolution of a terminal epoxide with phenol.
  02/2001;
• Article: Design and Synthesis of 13,14-Dihydro Prostaglandin F1α Analogues as Potent and Selective Ligands for the Human FP Receptor

  Yili Wang, John A. Wos, Michelle J. Dirr, David L. Soper, Mitchell A. deLong, Glen E. Mieling, Biswanath De, Jack S. Amburgey, Eric G. Suchanek, Cynthia J. Taylor
  [show abstract] [hide abstract]
  ABSTRACT: The in vitro evaluation of a new class of potential bone anabolic agents for the treatment of osteoporosis is described. These compounds are potent and selective ligands for the human prostaglandin F receptor (hFP receptor). The compounds lack the olefin unsaturation required for potency in the natural ligand PGF2α yet retain binding affinity for the hFP receptor in the nanomolar to micromolar range. Removal of the alkenes also results in a better selectivity ratio for the hFP receptor over the other prostaglandin receptors tested. A rationale for the selectivity differences of various analogues, based on ligand docking experiments to a putative hFP receptor model, is also described.
  02/2000;
• Article: Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1β converting enzyme (ICE) inhibitors

  David L. Soper, Justin X. Sheville, Steven V. O’Neil, Yili Wang, Michael C. Laufersweiler, Kofi A. Oppong, John A. Wos, Christopher D. Ellis, Mark W. Baize, Jack J. Chen, [......], Richard L. Wang, William P. Schwecke, Charles A. Cruze, Maria Buchalova, Marina Belkin, Fred Wireko, Amanda Ritter, Biswanath De, Difei Wang, Thomas P. Demuth Jr
  Bioorganic & Medicinal Chemistry. 14(23):7880-7892.